Boundless Bio, Inc. (BOLD) stock
BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.46+0.01 (+0.41%)
Close on Nov 11, 2026Market cap $55.96MP/E –Yield –
Boundless Bio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Boundless Bio's ebitda for the twelve months ending Sep 30, 2026 was -$57.07M. For fiscal 2025 it was -$62.30M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.30M | – |
| FY2024 | Dec 31, 2024 | -$72.18M | – |
| FY2023 | Dec 31, 2023 | -$53.84M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.10M | – |
| Q2 FY2026 | Jun 30, 2026 | -$23.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$18.42M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.89M | – |
See a number that looks wrong?